A candidate molecular signature associated with tamoxifen failure in primary breast cancer
about
GREB1 functions as a growth promoter and is modulated by IL6/STAT3 in breast cancerPrognostic significance of c-Met in breast cancer: a meta-analysis of 6010 casesDevelopment of multigene expression signature maps at the protein level from digitized immunohistochemistry slidesThe transcription factor REST is lost in aggressive breast cancer.Analysis of gene expression in PTHrP-/- mammary buds supports a role for BMP signaling and MMP2 in the initiation of ductal morphogenesis.Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer.Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG studyProlactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer.IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors.Network insights on oxaliplatin anti-cancer mechanisms.The immune system and inflammation in breast cancer.O-GlcNAcylation-inducing treatments inhibit estrogen receptor α expression and confer resistance to 4-OH-tamoxifen in human breast cancer-derived MCF-7 cells.Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression.Emerging roles for the pro-oncogenic anterior gradient-2 in cancer development.Epigenetic perspectives on cancer chemotherapy response.Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes.The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone.Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors.A functional interplay between ZNF217 and estrogen receptor alpha exists in luminal breast cancers.miR-451a Inhibited Cell Proliferation and Enhanced Tamoxifen Sensitive in Breast Cancer via Macrophage Migration Inhibitory FactorApproaches towards expression profiling the response to treatment.A five-gene model predicts clinical outcome in ER+/PR+, early-stage breast cancers treated with adjuvant tamoxifen.
P2860
Q21560759-B5661592-31FD-42CC-BD83-5C53C381902BQ28087523-7F19C852-825F-488C-A74A-3C72112BE4DAQ28731283-D96160E8-E1A8-4B0F-849A-360562B4DDB4Q33604808-F6EE376E-271F-4258-AC59-34A1D01BE038Q33822636-DEB08B63-8E69-4F20-B0F4-4A3F47D57A80Q34048134-D2F5026F-B8BF-492A-99E0-657AC2486FCFQ34559124-10D4FC49-706B-4B6E-A11B-625E7674FD68Q35029548-A055E5F8-2C7E-4864-ACC8-126E78945F80Q35836632-C1340524-0F6F-41F1-A23F-E0CA01B87CDAQ36578240-0A60015F-A951-45A1-8C1E-90CE870EBA6DQ37033451-1BBDE4CC-7B8D-49D4-B4DF-BAC0CD38AFFCQ37062403-9CFF847D-CF8F-4785-894B-DC003C6EFE96Q37690429-891533F9-A286-4E99-9AE6-A2B426983A53Q38040355-1A4E84F5-EFF0-4495-AD70-5BE810A608D8Q38209574-0B7995C1-3FD1-456D-9B63-D90A22BEC89FQ38410339-BCF5ECBD-398E-43C0-80F4-3ABACBD9D19EQ38756694-72399FF7-57E5-4F2C-9C70-F2B5A76CF7F7Q38859693-55BBC87B-5EA7-402D-8067-2214BFECCA33Q38980243-48423BDB-C947-4C7C-929B-B6633686FE36Q40751700-9FDE1C73-601F-4816-8481-19C2F3C2C212Q43161298-B3C583D6-C034-4402-A27A-FE11DEF96BC0Q44811677-9972FDA2-599F-4BCE-859B-803D9EFD10FE
P2860
A candidate molecular signature associated with tamoxifen failure in primary breast cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A candidate molecular signatur ...... ilure in primary breast cancer
@en
A candidate molecular signatur ...... lure in primary breast cancer.
@nl
type
label
A candidate molecular signatur ...... ilure in primary breast cancer
@en
A candidate molecular signatur ...... lure in primary breast cancer.
@nl
prefLabel
A candidate molecular signatur ...... ilure in primary breast cancer
@en
A candidate molecular signatur ...... lure in primary breast cancer.
@nl
P2093
P2860
P356
P1476
A candidate molecular signatur ...... ilure in primary breast cancer
@en
P2093
Agathe Bajard
Alastair M Thompson
Catherine Nguyen
Julie A Vendrell
Katherine E Robertson
Pascale A Cohen
Patrice Ravel
Sirwan M Hadad
Susan E Bray
Sylvie Chabaud
P2860
P2888
P356
10.1186/BCR2158
P577
2008-10-17T00:00:00Z
P5875
P6179
1011925419